Research Article
Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients
Table 1
The baseline characteristics of patients of both groups.
| | Variable | HCV positive
(group A; = 7)
Number (%) | HCV negative
(group B; = 21)
Number (%) | value |
| | Age (years) | | | | | Median (range) | 49 (34–66) | 49 (19–73) | 0.58 | | Gender | | | | | (i) Male | 5 (71.4%) | 13 (61.9%) | 0.65 | | (ii) Female | 2 (28.6%) | 8 (38.1%) | | B symptoms | 5 (71.4%) | 11 (52.4%) | 0.66 | | Performance status | | | | | (i) 0-1 | 6 (85.7%) | 12 (57.1%) | 0.36 | | (ii) >1 | 1 (14.3%) | 9 (42.9%) | | Elevated LDH | 5 (71.4%) | 14 (66.7%) | 0.82 | | DLBCL stage | | | | | (i) I | 0 (0%) | 3 (14.3%) | 0.67 | | (ii) II | 3 (42.9%) | 9 (42.9%) | | (iii) III | 3 (42.9%) | 6 (28.5%) | | (iv) IV | 1 (14.2%) | 3 (14.3%) | | BM involvement | 1 (14.3%) | 1 (4.8%) | 0.44 | | Splenomegaly (only) | 3 (42.9%) | 8 (38.1%) | 0.82 | | Splenic involvement | 3 (42.9%) | 0 (0%) | 0.01* | | Hepatomegaly (only) | 3 (42.9%) | 10 (47.6%) | 0.82 | | Hepatic involvement | 0 (0%) | 1 (4.8%) | 0.56 | | Extranodal sites | | | | | (i) 1 | 0 (0%) | 4 (14.3%) | 0.64 | | (ii) 2 | 1 (14.3%) | 2 (9.5%) | | R.IPI | | | | | (i) Very good | 0 (0%) | 7 (33.3%) | 0.19 | | (ii) Good | 6 (85.7%) | 11 (52.4%) | | (iii) Poor | 1 (14.3%) | 3 (14.3%) |
|
|
means significant ( < 0.05).
|
